The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound.
The authors report the findings of in vivo studies of XF-70 (a novel, dicationic porphyrin) against Staphylococcus aureus in a murine model of a burn wound infection. Mice received a 15% total body scald burn wound, which were inoculated with S. aureus (1.8 x 10 CFU). After 24 hours, escharectomies were performed and groups (n = 8) received single or two doses (6 hours apart) of XF-70* (100 microg/wound) or silver sulfadiazine, Acticoat, or saline applied topically. Viable bacteria were quantified from homogenized burn tissue biopsies and the spleen by plating dilutions onto agar plates and CFU determination. A single dose of XF-70 reduced bacterial burden by 98.77% (untreated: 2.78 +/- 2.96 x 10 CFU/g vs XF-70 treated: 3.4 +/- 0.19 x 10 CFU/g, P < .01). Two XF-70 doses reduced the growth of S. aureus by 99.96% (1.2 +/- 0.6 x 10 CFU/g, P < .01). These results were similar to the results obtained from commonly used topical antibacterials silver sulfadiazine and Acticoat. The spleens of mice treated with saline had a robust growth of S. aureus (7.0 +/- 1.97 x 10 CFU/g) whereas those treated with one or two XF-70 doses grew only 3.5 +/- 0.002 x 10 CFU/g and 5.7 +/- 0.002 x 10 CFU/g, respectively, a significant (P < .001) reduction in S. aureus dissemination. Single and multiple doses of XF-70 were effective in controlling S. aureus growth in burn wounds and inhibited systemic dissemination of S. aureus. Early treatment of burn wounds with XF-70 may be effective in slowing bacterial dissemination to other tissues.
Hurtuk
Michael G
MG
Department of Surgery, Burn Shock Trauma Institute, Loyola University Medical Center, Maywood, Illinois 60153, USA.
He
L-K
LK
Szilagyi
Andrea
A
Gamelli
Richard L
RL
Hecht
David W
DW
Kennedy
Richard H
RH
Rhys-Williams
William
W
Love
William G
WG
Shankar
Ravi
R
D000287:Administration, Topical; D000704:Analysis of Variance; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000601:surgery; D024901:Drug Resistance, Multiple, Bacterial; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D011091:Polyesters; D011095:Polyethylenes; D011166:Porphyrins / Q000008:administration & dosage / Q000627:therapeutic use*; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000627:therapeutic use; D013154:Spleen / Q000187:drug effects / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D014946:Wound Infection / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology
C117408:Acticoat; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D011091:Polyesters; D011095:Polyethylenes; D011166:Porphyrins; C547327:XF-70 compound; D012837:Silver Sulfadiazine